

## IL28B and ITPA Single Nucleotide Polymorphisms in a Cohort of Patients with HCV and HCV/HIV, Southern Brazil

Avanzi VM<sup>1</sup>, Vicente BA<sup>2</sup>, Gomes-da-Silva MM<sup>2</sup>, Vidal LRR<sup>3</sup>, Nogueira MB<sup>3</sup>, Tuon FF<sup>1,2</sup> and Raboni SM<sup>1,2\*</sup>

<sup>1</sup>Postgraduate Program in Internal Medicine and Health Science, Universidade Federal do Paraná, Brazil

<sup>2</sup>Infectious Diseases Division, Universidade Federal do Paraná, Brazil

<sup>3</sup>Laboratory of Virology, Universidade Federal do Paraná, Brazil

### Abstract

**Objective:** The aim of this study is to describe the single nucleotide polymorphisms (SNP) in human genes for IL28B and ITPA of HIV/HCV coinfecting patients followed at a referral Hospital of Universidade Federal do Paraná (UFPR).

**Methods:** A cross-sectional study was carried out. HIV/HCV coinfecting and HCV mono-infected patients were enrolled. Clinical and epidemiological data from medical records were reviewed, and peripheral blood was collected to analyze the IL28B and ITPA SNPs.

**Results:** A total of 37 HCV- and 41 HCV/HIV-positive subjects were included in the study, 13 (35.1%) mono-infected subjects were previously treated, 12 (92.3%) with PEG-INF $\alpha$ /RBV and of these, 8 (61.5%) had sustained virological response (SVR). Regarding HCV/HIV coinfecting patients, 23 (56.1%) received treatment with PEG-INF $\alpha$ /RBV and 12 (52.1%) had SVR. IL28B CC genotype was found in all HCV mono-infected patients and in 56.5% of coinfecting subjects. Regarding ribavirin-induced anemia, all patients showed the ITPA SNP favorable for this event, and anemia was present in 38.5% of mono-infected and in 65.2% of coinfecting patients.

**Conclusion:** With the availability of direct-acting antivirals (DAAs) for the treatment of chronic infection by the hepatitis C virus, free-INF regimens have been implemented worldwide. However, in the setting of HIV/HCV coinfection ribavirin will continue to compose some therapeutic schemes. Thus, tests related to genetic markers that influence the response to HCV treatment should be recommended in pretreatment, since results would benefit both the patient and the public healthcare system, guiding rational drug use in situations where responses to treatment are particularly low and adverse effects are high.

**Keywords:** Coinfection; HIV/HCV; HIV; HCV; SNP; IL28B; ITPA

### Background

The prevalence of HIV/HCV coinfection in Brazil ranges from 3.3% to 82.4% with average of 20.3% [1]. HIV/HCV coinfection is a significant risk factor for liver fibrosis, since HIV seropositivity and low CD4+ counts seem to accelerate this process [2,3]. In addition, HCV infection has been shown to be associated with faster progression to acquired immunodeficiency syndrome (AIDS) [4]. Until 2011, the standard treatment of chronic hepatitis C consisted of a combination of pegylated-interferon-alpha plus ribavirin (PEG-INF $\alpha$ /RBV).

Currently, a new era in the treatment of chronic HCV infection began with the approval of direct-acting antiviral drugs (DAAs) oral medications in interferon-free regimens. However, in HIV/HCV coinfection the PEG-INF $\alpha$ /RBV combination remains recommended [5].

Therefore, the evaluation of prediction of sustained virological response (SVR) to PEG-INF $\alpha$  based therapy must be maintained seeking to identify patients with high chance to cure and, consequently, candidates for this therapy and those with low chance to respond to PEG-INF $\alpha$ /RBV, candidates for interferon-free therapies. Moreover, treatment failure is likely to occur due to inherent viral and host factors such as the presence of certain SNPs and inappropriate drug regimens [6] and deeper analysis of non-response may help elucidate its molecular mechanisms [7].

In this setting, genetic variation in interleukin 28B (IL28B) and inosine triphosphatase (ITPA) genes are known host genetic factors that play a vital role in the clearance of HCV infection and in the risk of ribavirin-induced hematologic toxicity, respectively [8]. Currently, with

reports of therapeutic failure to DAAs, it has been recommended to evaluate viral and host factors predictors of treatment efficacy, among which are cited resistance-associated variants (RAVs) detection and IL28B SNPs [9]. Besides that, data on HIV/HCV coinfecting patients and the impact of host IL28B and ITPA SNPs on treatment response and toxicity in Brazilian patients are scarce. In this study we describe the epidemiological, genetic and clinical profile of a cohort of HIV/HCV coinfecting patients in follow up in a tertiary care academic hospital in Southern Brazil.

### Methods

#### Study subjects

A cross-sectional study was carried out, in which HIV/HCV coinfecting outpatients identified in reference clinics of Hospital de Clínicas - Universidade Federal do Paraná (HC/UFPR) were prospectively included from March 2011 to April 2016. HCV or HIV/

\*Corresponding author: Raboni SM, Infectious Diseases Division, Universidade Federal do Paraná, Rua General Carneiro, 180, 3rd floor, 82060-900 Curitiba, PR, Brazil, Tel: +55 41 33607974; Fax: +55 41 33601811; E-mail: [sraboni@ufpr.br](mailto:sraboni@ufpr.br)

Received July 25, 2016; Accepted August 11, 2016; Published August 18, 2016

**Citation:** Avanzi VM, Vicente BA, Gomes-da-Silva MM, Vidal LRR, Nogueira MB, et al. (2016) IL28B and ITPA Single Nucleotide Polymorphisms in a Cohort of Patients with HCV and HCV/HIV, Southern Brazil. J AIDS Clin Res 7: 610. doi: 10.4172/2155-6113.1000610

**Copyright:** © 2016 Avanzi VM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

HCV coinfecting patients were enrolled in the study. Patients with incomplete medical information, children and those who did not agree to participate in the study were excluded. All information related to clinical, demographics and epidemiological data were obtained through a structured questionnaire and medical record reviews. Included patients were submitted to a collection of 5 mL venous blood. The Institutional Review Board of HC/UFPR approved the study (IRB# 34716414.9.0000.0096).

## Genotyping

The SNP rs12979860 in the region of the IL28B gene was carried out by confronting two-pair primers (CTPP), as previously reported [10]. SNPs rs1127354 and rs7270101 in chromosome 20 for ITPA gene were performed using the ABI TaqMan allelic discrimination kit and the ABI7900HT Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA), as previously described [11]. The possible genotypes for each biallelic polymorphism are rs1127354: C/C, A/C, A/A (minor allele=A); rs7270101: A/A, A/C, C/C (minor allele=C). ITPase activity was defined by the presence of minor alleles at the respective polymorphic sites [11,12]. ITPA deficiency has been grouped into none; mild (>60% activity); moderate (30–60% activity); and severe (<30% activity).

## Statistical analyses

Demographics, epidemiological, clinical and genetic data were compiled and analyzed using GraphPad Prism<sup>®</sup> software version 5.03 (Graph Pad Software Inc., La Jolla, CA, USA). Baseline demographics and clinical characteristics with normal and non-normal distributions were presented as means ± standard deviations and medians with interquartile ranges (IQR), respectively. The Fisher's exact test, chi-squared test, or Wilcoxon-Mann-Whitney test were used where appropriate. The significance level was set at P<0.05.

## Results

A total of 37 HCV- and 41 HCV/HIV-positive subjects were included in the study. The demographics, clinical and virological data of the study population are described in Table 1. Regarding HCV therapy, 13 (35%) monoinfected subjects were treated, 12 (92%) with PEG-INFα/RBV and one (8%) with simeprevir and sofosbuvir. Among treated patients, 8 (61.5%) had SVR, 4 (31%) had null response and 1 (8%) relapsed. Only 2 (15%) patients had liver biopsy and both presented fibrosis. Regarding HCV/HIV coinfecting patients, 23 (56%) were treated for HCV with PEG-INFα/RBV. Of these, 12 (52%) had SVR, 9 (39%) had null response and 2 (9%) relapsed. Twenty (49%) patients had liver biopsy and 18 (90%) had fibrosis, 14 (70%) had hepatic steatosis, 6 (30%) presented cirrhosis, and only one (5%) showed no liver disorders. Additionally, 3 (7%) patients died, two due to liver complications. The results of the IL28B genotype (SNP rs12979860) and the relationship with the response to treatment, as well as the genotype for ITPA SNPs (rs7270101 and rs1127354) and the ribavirin-induced anemia are shown in Figure 1. The predicted ITPase activity distribution according to compound genotype of rs7270101 and rs1127354, as previously determined by biochemical analyses, is shown in Table 2.


## Discussion

The efficacy of PEG-INFα/RBV treatment depends, in part, on the interaction of virus and host factors [13], and SNPs may be associated with the outcome and response to treatment, specially IL28B and ITPA genotypes have been reported to be significant markers in recent trials [14,15]. For IL28B SNPs, SVR rates were higher in CC patients (54% in monoinfected patients and 67% in coinfecting patients), findings similar to those reported in other studies [16-18]. Despite that, no significance was found, probably as a consequence of the small number of patients in both groups.

Characteristics	Monoinfected HCV (n=37)	Coinfected HCV/HIV-1 (n=41)	p-value
	N (%)	N (%)	
<b>Gender</b>			
Male	21 (57)	28 (68)	0.3515
Female	16 (43)	13 (32)	
<b>Age (Years/Median/IQR)</b>	54 (40-78)	49 (46-75)	0.3755
<b>Hepatitis diagnosis time (Years/Median/IQR)</b>	2 (1 – 21)	10 (7-23)	<b>&lt;0.0001</b>
<b>HCV genotype</b>			
1	18 (49)	25 (61)	0.1306
3	15 (41)	9 (22)	
Other <sup>1</sup>	0	2 (5)	
NG	4 (10)	5 (12)	
<b>HCV therapy</b>			
Yes	13 (35)	23 (56)	0.0733
PEG/RIB	12 (92)	23 (100)	
Other <sup>2</sup>	1 (8)	0	
No	24 (65)	18 (44)	
<b>HIV-1 diagnosis time (Years/Median/IQR)</b>	-	15 (11-25)	-
<b>ART use</b>		41 (100)	-
<b>HIV-1 viral load</b>			
Detectable (>40 copies/mL)	-	9 (22.0)	-
Undetectable (<40 copies/mL)	-	32 (78.0)	-
<b>CD4+ LT value (cell/mm<sup>3</sup>/ median/IQR)</b>			
Nadir	-	149 (83-445)	-
Current	-	447 (290–1038)	-

IQR: Interquartile Range; NI: Not Informed; NG: Not Genotyped; Other<sup>1</sup>: Genotyping 2 And 4; Other<sup>2</sup>: Simeprevir/Sofosbuvir; ART: Antiretroviral Therapy; In Bold: Significant Difference

**Table 1:** Demographics, clinical and virological data of the study population.



**Figure 1:** IL28B and ITPA polymorphism, response to treatment and anemia in HCV monoinfected and HCV/HIV coinfecting patients. **A.** IL28B rs12979860 SNP and response to treatment. **B.** ITPA rs7270101 SNP and anemia. **C.** ITPA rs1127354 SNP and anemia.

rs 7270101	rs 1127354	Predicted ITPase Activity (%)	Predicted ITPase Deficiency	HCV	Anemia (%)	HCV/HIV	Anemia (%)
AA	CC	100	-	7	3 (43)	12	7 (58)
AC	CC	60	+	3	2 (67)	5	2 (40)
AA	CA	30	++	1	0	2	0
CC	CC	30	++	1	0	0	0
AC	CA	10	+++	0	0	0	0
AA	AA	<5	+++	0	0	0	0

Note: Definition of an ITPase deficiency is variable according to rs7270101/rs1127354 genotypes: severity of ITPase deficiency was predicted as absent, representing wild-type activity (-), mild (+), moderate (++), or severe (+++) deficiency, according to previously study (31)

**Table 2:** Distribution of predicted ITPase activity according to compound genotype of rs7270101 and rs1127354 as previously determined by biochemical analyses in monoinfected (HCV) and coinfecting (HCV/HIV) patients.

Previously, Bertol et al. [19] evaluated the frequency of CC genotype in Southern Brazil, it was found in 31% of HCV monoinfected and 23.5% of HIV/HCV patients. SVR was not evaluated.

It has been suggested that SNPs close to the IL28B gene have significant influence on the establishment of HCV infection in monoinfected patients, contributing to a better understanding of the

susceptibility, natural history of HCV infection, and high rate of SRV in this patient group [16]. However, in the setting of HIV infection, Martin et al. [20] and Nattermann et al. did not find any correlation between the SNP rs12979860 and HIV mono-infected patients; there was no significant difference in the susceptibility to HIV infection, disease progression, or the clinical and laboratory parameters, such as viral load. Therefore, SNPs of the IL28B gene seem to be associated with HIV patients only when they are coinfected with HCV [21].

The ITPA gene encodes inosine triphosphate (ITPase) that catalyzes the conversion of inosine triphosphate (ITP) to inosine monophosphate (IMP) and pyrophosphate (Pi), and thus the ITP does not accumulate in normal cells. ITP is used to keep the adenosine triphosphate (ATP) in red blood cells, consequently preventing oxidative stress. The ITPase deficiency interrupts this cycle, leading to an accumulation of ITP in cells [22,23]. The RBV is incorporated into erythrocytes, undergoing phosphorylation to its pharmacologically active form through adenosine kinase. The ribavirin triphosphate is unable to cross the cell membrane of erythrocytes and accumulates intracellularly, thus causing oxidative damage and leading to hemolysis [24]. The ITPase deficiency causes the ITP accumulation in erythrocytes that can compete with RBV triphosphate, consequently protecting the RBV-induced hemolysis [25-27].

ITPase activity modulates the association between RBV and hemolysis, but there is no correlation with hemoglobin (Hb) decline, which has no impact on treatment response. Models suggest that ITPase activity has no direct influence on treatment response. The data confirm the strong protective effect of ITPase deficiency against Hb decline during PEG-INF $\alpha$ /RBV treatment. Furthermore, ITPase deficiency was associated with a higher cumulative RBV dosage, and yet was not associated with SVR [28].

In this study, all patients treated and genotyped for ITPA SNPs had at least one favorable genotype for the development of anemia. Among mono-infected patients, 42% had anemia caused by ribavirin and 45% of coinfected patients presented this event. In a study performed by Delvaux et al. [29] in Brazilian patients with HCV, the allelic distribution frequency of SNPs in rs7270101 and rs1127354 showed high rates of AA and CC genotypes, respectively, suggesting that the study population are greatly prone to develop RBV-induced anemia. To our knowledge, this is the first report of the frequency of ITPA gene polymorphisms in a cohort of Brazilian patients coinfected with HCV/HIV. In HIV-1 infected adults on stable, contemporary ART, the prevalence of anemia was high [30] and in patients coinfected with HCV in RBV anemia may be more severe.

Because of the small number of study participants, it was not possible to evaluate the impact of SNPs in response to treatment of HCV. Besides that, studies about the SNP related to the response and toxicity to treatment in Brazil is recent. Similar to previous studies, they should be recommended in pretreatment period, when results could benefit not only the patients but also the public healthcare system, guiding the rational use of drugs in situations where treatment response rates are particularly low and adverse effects are high.

## References

1. Kuehlkamp VM, Schuelter-Trevisol F (2013) Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: A review. *Brazilian J Infect Dis* 17: 455-463.
2. Ragni MV, Belle SH (2001) Impact of human immunodeficiency Virus infection on progression to end-stage liver disease in individuals with Hemophilia and Hepatitis C Virus infection. *J Infect Dis* 183: 1112-1115.
3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology* 30: 1054-1058.
4. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, et al. (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 192: 992-1002.
5. CONITEC (2015) Protocolo clínico e diretrizes terapêuticas para hepatite C e coinfeções. Programa Nacional de DST/Aids, Ministério da Saúde - Dep DST, Aids e Hepatites Virais, Brazil.
6. Strahotin CS, Babich M (2012) Hepatitis C variability, patterns of resistance and impact on therapy. *Adv Virol* 267483.
7. Estrabaud E, Appourchaux K, Bièche I, Carrat F, Lapalus M, et al. (2015) IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C. *PLoS One* 10: e0121395.
8. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464: 405-408.
9. Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, et al. (2016) Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. *J Med Virol* .
10. Ferreira Cda S, Abreu RM, da Silva MC, Ferreira AS, Nasser PD, et al. (2013) A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. *PLoS One* 8: e78142.
11. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, et al. (2010) Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. *Gastroenterology* 139: 1181-1189.
12. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, et al. (2011) Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. *Hepatology* 53: 389-395.
13. Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, et al. (2013) Role of viral and host factors in interferon based therapy of hepatitis C virus infection. *Virol J* 10: 299.
14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461: 399-401.
15. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464: 405-408.
16. Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, et al. (2014) Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. *PLoS One* 9: e99126.
17. De Nicola S, Aghemo A, Grazia Rumi M, Galmozzi E, Valenti L, et al. (2012) Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. *Hepatology* 55: 336-342.
18. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 41: 1100-1104.
19. Bertol BC, Moreira S, Garcia RF, Ferreira LE, Debortoli G, et al. (2015) IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. *Front Microbiol* 6: 153.
20. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, et al. (2010) IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. *J Infect Dis* 202: 1749-1753.
21. Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, et al. (2011) Genetic Variation in IL28B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C. *J Infect Dis* 203: 595-601.
22. Cao H, Hegele RA (2002) DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. *J Hum Genet* 47: 620-622.
23. Maeda T, Sumi S, Ueta A, Ohkubo Y, Ito T, Marinaki AM, et al. (2005) Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. *Mol Genet Metab* 85: 271-279.

- 
24. Keffe EB, Kowdley KV (2005) Hematologic side effects of interferon and ribavirin therapy. *J Clin Gastroenterol* 39: S3-S8.
25. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N (2006) Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. *Clin Chem* 52: 240-247.
26. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, et al. (2010) ITPA gene variant protects against anemia induced by pegylated interferon- $\alpha$  and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 40: 1063-1071.
27. Kim JS, Ahn SM, Jung YK, Kwon OS, Kim YS, et al. (2013) The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. *J Korean Med Sci* 28: 1213-1219.
28. Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, et al. (2014) ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. *Hepatology* 59: 2152-2160.
29. Delvaux N, Costa VD Da, Costa MM Da, Villar LM, Coelho HSM, et al. (2015) Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C. *Mem Inst Oswaldo Cruz* 110: 636-643.
30. Lipshultz HM, Hileman CO, Ahuja S, Funderburg NT, McComsey GA (2015) Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy. *Antivir Ther* 20: 521-527.